In this article:

Idera (IDRA) Gets a Hold Rating from JMP Securities

In this article:
In this article:

In a report released today, Reni Benjamin from JMP Securities maintained a Hold rating on Idera (IDRAResearch Report). The company’s shares closed last Monday at $0.58, close to its 52-week low of $0.57.

According to TipRanks.com, Benjamin ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.6% and a 34.3% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.

Idera has an analyst consensus of Hold.

See Insiders’ Hot Stocks on TipRanks >>

Based on Idera’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.97 million. In comparison, last year the company had a GAAP net loss of $20.55 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.

Read More on IDRA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed